


## VHL Antibody (F49682)


Catalog No.	Formulation	Size
F49682-0.4ML	In 1X PBS, pH 7.4, with 0.09% sodium azide	0.4 ml
F49682-0.08ML	In 1X PBS, pH 7.4, with 0.09% sodium azide	0.08 ml

[Bulk quote request](#)


<b>Availability</b>	1-3 business days
<b>Species Reactivity</b>	Human
<b>Format</b>	Purified
<b>Clonality</b>	Polyclonal (rabbit origin)
<b>Isotype</b>	Rabbit Ig
<b>Purity</b>	Purified
<b>UniProt</b>	P40337
<b>Applications</b>	Western Blot : 1:1000 IHC (Paraffin) : 1:50-1:100 Flow Cytometry : 1:10-1:50
<b>Limitations</b>	This VHL antibody is available for research use only.



Western blot analysis of VHL antibody and HepG2 lysate.



VHL antibody IHC analysis in formalin fixed and paraffin embedded mouse brain tissue.



VHL antibody flow cytometric analysis of HepG2 cells (green) compared to a [negative control](#) (blue). FITC-conjugated goat-anti-rabbit secondary Ab was used for the analysis.

## Description

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.

## Application Notes

Titration of the VHL antibody may be required due to differences in protocols and secondary/substrate sensitivity.

## Immunogen

A portion of amino acids 181-210 from the human protein was used as the immunogen for this VHL antibody.

## Storage

Aliquot the VHL antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.